TXA₂/TP Antagonist

TXA₂/TP Antagonists (26):

Cat. No.	Product Name	Effect	Purity

HY-50901

ONO-AE3-208	Antagonist	98.65%
ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a K_i of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (K_i of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.

HY-50175

Laropiprant	Antagonist	99.34%
Laropiprant is a potent and selective DP receptor antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.

HY-101235

ICI 185282	Antagonist
ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619 (HY-108566)-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD₂ (HY-101988), PGF_2α (HY-12956), arachidonic acid (HY-109590), LTD₄ and PAF (HY-108635) in vivo. ICI 185282 can be used for bronchial asthma research.

HY-19132

CGS-22652	Antagonist
CGS 22652 is a potent thromboxane A2 receptor antagonist. CGS 22652 has selective thromboxane A2 synthase inhibitory properties. CGS 22652 can be used in the research of coronary artery thrombosis.

HY-B0745

Ramatroban	Antagonist	99.10%
Ramatroban is a selective thromboxane A₂ (TxA₂, IC₅₀=14 nM) antagonist, which also antagonizes CRTH2 (IC₅₀=113 nM) by inhibiting PGD₂ binding.

HY-B0774

Seratrodast	Antagonist	99.59%
Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity.

HY-129851

NTP42	Antagonist	98.58%
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619. NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH).

HY-108563A

SC 51089 free base	Antagonist	98.60%
SC 51089 free base is a selective antagonist of prostaglandin E₂ EP1 receptor, with K_is of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity.

HY-121018

Daltroban	Antagonist	98.1%
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.

HY-15853

MK-7246	Antagonist	99.63%
MK-7246 is a potent and selective CRTH2 antagonist with a K_i of 2.5±0.5 nM.

HY-111271A

L 888607 Racemate	Antagonist	99.81%
L 888607 Racemate is a selective prostaglandin D₂ receptor subtype 1 (DP1) antagonist, with K_is of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.

HY-U00253

KP496	Antagonist	99.79%
KP496 is a selective, dual antagonist for Leukotriene D4 receptor and Thromboxane A2 receptor.

HY-108563

SC 51089	Antagonist
SC 51089 is a selective antagonist of prostaglandin E₂ EP1 receptor, with K_is of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 exhibits neuroprotective activity.

HY-158332

Sulotroban	Antagonist	99.29%
Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation.

HY-105218

Ifetroban	Antagonist	99.65%
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research.

HY-50175A

Laropiprant sodium	Antagonist
Laropiprant sodium is a potent and selective DP receptor antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.

HY-118044

I-SAP	Antagonist
I-SAP is a radioiodinated TXA2/PGH2 receptor antagonist. The bind between I-SAP and the receptors, is inhibited by the histidine modifying reagent diethyl-pyrocarbonate (DEPC).

HY-179246

CXT29	Antagonist
CXT29 is an orally active COX-2 inhibitor and a thromboxane A₂ receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC₅₀ values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC₅₀ of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases.

HY-B0745S

Ramatroban-d₄	Antagonist
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-101700A

LCB 2853 sodium	Antagonist
LCB 2853 (sodium) is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 (sodium) exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 (sodium) can be used for the research of cardiovascular disease, such as hypertension.

Name
Email *

	Sorry, but the email address you supplied was invalid.